Life Science News

Sunstone Life Science Ventures Fund I portfolio company Nuevolution A/S today announced that it has entered into collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, using Nuevolution’s proprietary Chemetics® drug discovery platform. The collaboration was facilitated by Johnson & Johnson Innovation, in partnership with Janssen Discovery Sciences.

 

 

Sunstone Life Science portfolio company Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer, today announced that it has entered into a definitive agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Under the agreement, Janssen, will be granted an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013. The collaboration was facilitated by the Johnson & Johnson Innovation Center in London. Currently in Phase I clinical trials, ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells. Stimulation of CD40 on dendritic cells initiates a process leading to a dramatic increase in T effector cells attacking the tumor. In addition, a tumor-specific memory is established leading to long term immunity to the cancer.

 

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces that Dr. J. Donald (Don) deBethizy has been appointed as Chairman of the Board of Directors. He replaces outgoing Chairman Prof. Dr. Gunther Hartmann who co-founded Rigontec and led the Board since 2014. Prof. Hartmann will remain on the Board of Directors. Dr. deBethizy brings more than 30 years  of experience in research and development, as well as financial and operational management in the biotechnology and consumer products industry. He is currently President of White City Consulting ApS in Denmark and serves on the supervisory boards of arGEN-X NV (Euronext Brussels), Newron Pharmaceuticals SPA (SIX Swiss Exchange), Serendex Pharmaceuticals (Oslo Exchange) and Noxxon Pharma AG.

Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, today announced the appointment of Kim Simonsen, MD, as Chief Development Officer. Mr. Simonsen will head Anergis’ global product development from preclinical development to registration, including CMC, clinical development, regulatory affairs and global project management.

Kim Simonsen joins Anergis from Ablynx NV, where he was Chief Operations Officer. Prior to that, he was Senior Director, Global Clinical Development, at ALK Abello A/S, where he led the clinical development of Grazax®, the first marketed grass pollen allergy immunotherapy tablet. From 2000 to 2005, Mr. Simonsen was Chief Executive Officer of the CRO Medicon A/S after having held various clinical development roles at big pharmaceutical companies, e.g. as Medical Director of Novartis Healthcare A/S, Director of Clinical Operations at Novo Nordisk A/S, and as Medical Director and Clinical Expert at Sandoz A/S.

 

Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, today announced treatment completion of its Phase II clinical trial of AllerT, a novel long-peptide immunotherapeutic to treat birch pollen allergies. In the trial, 213 patients were randomized to receive target doses of 10, 25 or 50 μg of AllerT or placebo as 5 subcutaneous injections over 2 months. The last patient was treated at the end of March. No serious adverse events and no grade 3 or 4 allergic reactions were reported. The trial is being conducted in Canada and is still blinded. Results are expected in Q3 of 2015.